secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001493152-25-024556
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025
--------------------------------------------------------------------------------

- 12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.
- Phase 3 THIO-104 screening has begun; CEO cites 17.8 months median OS observed in Phase 2 as potential basis for early FDA approval.
- A patient treated in March 2023 showed survival of 30 months (912 days) as of September 17, 2025.
- Posters presented at SITC 2025 detail Phase 2 and Phase 3 trial designs for ateganosine + cemiplimab in advanced NSCLC.
- FDA has granted Fast Track designation for ateganosine in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/0001493152-25-024556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer